A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease

INTRODUCTION: Despite significant progress, a disease-modifying therapy for Alzheimer’s disease (AD) has not yet been developed. Recent findings implicate soluble oligomeric amyloid beta as the most relevant protein conformation in AD pathogenesis. We recently described a signaling cascade whereby o...

Descripción completa

Detalles Bibliográficos
Autores principales: Nygaard, Haakon B, Wagner, Allison F, Bowen, Garrett S, Good, Susan P, MacAvoy, Martha G, Strittmatter, Kurt A, Kaufman, Adam C, Rosenberg, Brian J, Sekine-Konno, Tomoko, Varma, Pradeep, Chen, Kewei, Koleske, Anthony J, Reiman, Eric M, Strittmatter, Stephen M, van Dyck, Christopher H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396171/
https://www.ncbi.nlm.nih.gov/pubmed/25874001
http://dx.doi.org/10.1186/s13195-015-0119-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396171/
https://www.ncbi.nlm.nih.gov/pubmed/25874001
http://dx.doi.org/10.1186/s13195-015-0119-0

Ejemplares similares